Access to treatment among patients with advanced kidney cancer in Mexico
Objectives: In many cases, the socioeconomic status of patients diagnosed with metastatic renal cell carcinoma (mRCC) in developing countries could limit their access to the best available therapeutic options. We aimed to describe the clinical characteristics and access to treatment of Mexican patie...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Permanyer
2022-07-01
|
| Series: | Medicina Universitaria |
| Subjects: | |
| Online Access: | https://www.medicinauniversitaria.org/frame_esp.php?id=178 |
| _version_ | 1811234526438883328 |
|---|---|
| author | Carlos E. Salazar-Mejía Antonio Piñeiro-Martínez Angela L. Juárez-Villarreal Arianna E. Jara-Rios Ana P. Ibarra-Alaniz Blanca O. Wimer-Castillo David Hernández-Barajas Oscar Vidal-Gutiérrez Lauro Gómez-Guerra Omar A. Zayas-Villanueva |
| author_facet | Carlos E. Salazar-Mejía Antonio Piñeiro-Martínez Angela L. Juárez-Villarreal Arianna E. Jara-Rios Ana P. Ibarra-Alaniz Blanca O. Wimer-Castillo David Hernández-Barajas Oscar Vidal-Gutiérrez Lauro Gómez-Guerra Omar A. Zayas-Villanueva |
| author_sort | Carlos E. Salazar-Mejía |
| collection | DOAJ |
| description | Objectives: In many cases, the socioeconomic status of patients diagnosed with metastatic renal cell carcinoma (mRCC) in developing countries could limit their access to the best available therapeutic options. We aimed to describe the clinical characteristics and access to treatment of Mexican patients with mRCC. Materials and methods: We performed a retrospective analysis of all patients with a histopathologically confirmed diagnosis of renal cell carcinoma treated at an oncology referral center in Northeast Mexico over a 5-year period. Results: We included 233 patients in the analysis, of whom 63% were men. The mean age at diagnosis was 58.2 years; 87% of the tumors were histopathologically classified as clear cell carcinoma. Regarding laterality, 54% of the tumors originated from the right kidney. The distribution of cases by clinical stage (CS) was as follows: CS I 15%, CS II 8%, CS III 17%, and CS IV 60%. In terms of access to first-line systemic management in the 139 patients with advanced kidney cancer who were candidates for treatment, 29% received treatment with a single-drug tyrosine kinase inhibitor (TKI), 4% were treated with combined or single-drug immunotherapy (IO), and 12% were treated with TKI combined with IO. Fifty-five percentages of patients with the advanced disease did not have access to standard first-line therapy, and the rate of loss to medical follow-up was 69% of cases. Conclusions: Despite the proven oncological benefit of the latest generation of therapies based on IO/IO or IO/TKI for mRCC, access to first-line standard management is still poor in our country.
|
| first_indexed | 2024-04-12T11:37:49Z |
| format | Article |
| id | doaj.art-9e71d12c64f64857830c18049f2cb565 |
| institution | Directory Open Access Journal |
| issn | 1665-5796 2530-0709 |
| language | English |
| last_indexed | 2024-04-12T11:37:49Z |
| publishDate | 2022-07-01 |
| publisher | Permanyer |
| record_format | Article |
| series | Medicina Universitaria |
| spelling | doaj.art-9e71d12c64f64857830c18049f2cb5652022-12-22T03:34:46ZengPermanyerMedicina Universitaria1665-57962530-07092022-07-0124310.24875/RMU.22000054Access to treatment among patients with advanced kidney cancer in MexicoCarlos E. Salazar-Mejía0Antonio Piñeiro-Martínez1Angela L. Juárez-Villarreal2Arianna E. Jara-Rios3Ana P. Ibarra-Alaniz4Blanca O. Wimer-Castillo5David Hernández-Barajas6Oscar Vidal-Gutiérrez7Lauro Gómez-Guerra8Omar A. Zayas-Villanueva9Centro Universitario Contra el Cáncer, Oncology Service, School of Medicine and “Dr. José Eleuterio González” University Hospital and Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, MexicoDepartment of Urology. School of Medicine and “Dr. José Eleuterio González” University Hospital and Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, MexicoCentro Universitario Contra el Cáncer, Oncology Service, School of Medicine and “Dr. José Eleuterio González” University Hospital and Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, MexicoCentro Universitario Contra el Cáncer, Oncology Service, School of Medicine and “Dr. José Eleuterio González” University Hospital and Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, MexicoCentro Universitario Contra el Cáncer, Oncology Service,School of Medicine and “Dr. José Eleuterio González” University Hospital and Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, MexicoCentro Universitario Contra el Cáncer, Oncology Service, School of Medicine and “Dr. José Eleuterio González” University Hospital and Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, MexicoCentro Universitario Contra el Cáncer, Oncology Service, School of Medicine and “Dr. José Eleuterio González” University Hospital and Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, MexicoCentro Universitario Contra el Cáncer, Oncology Service; School of Medicine and “Dr. José Eleuterio González” University Hospital and Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, MexicoDepartment of Urology. School of Medicine and “Dr. José Eleuterio González” University Hospital and Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, MexicoCentro Universitario Contra el Cáncer, Oncology Service, School of Medicine and “Dr. José Eleuterio González” University Hospital and Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, MexicoObjectives: In many cases, the socioeconomic status of patients diagnosed with metastatic renal cell carcinoma (mRCC) in developing countries could limit their access to the best available therapeutic options. We aimed to describe the clinical characteristics and access to treatment of Mexican patients with mRCC. Materials and methods: We performed a retrospective analysis of all patients with a histopathologically confirmed diagnosis of renal cell carcinoma treated at an oncology referral center in Northeast Mexico over a 5-year period. Results: We included 233 patients in the analysis, of whom 63% were men. The mean age at diagnosis was 58.2 years; 87% of the tumors were histopathologically classified as clear cell carcinoma. Regarding laterality, 54% of the tumors originated from the right kidney. The distribution of cases by clinical stage (CS) was as follows: CS I 15%, CS II 8%, CS III 17%, and CS IV 60%. In terms of access to first-line systemic management in the 139 patients with advanced kidney cancer who were candidates for treatment, 29% received treatment with a single-drug tyrosine kinase inhibitor (TKI), 4% were treated with combined or single-drug immunotherapy (IO), and 12% were treated with TKI combined with IO. Fifty-five percentages of patients with the advanced disease did not have access to standard first-line therapy, and the rate of loss to medical follow-up was 69% of cases. Conclusions: Despite the proven oncological benefit of the latest generation of therapies based on IO/IO or IO/TKI for mRCC, access to first-line standard management is still poor in our country. https://www.medicinauniversitaria.org/frame_esp.php?id=178Kidney cancer. Advanced. Access to treatment. Mexico. Latin America. |
| spellingShingle | Carlos E. Salazar-Mejía Antonio Piñeiro-Martínez Angela L. Juárez-Villarreal Arianna E. Jara-Rios Ana P. Ibarra-Alaniz Blanca O. Wimer-Castillo David Hernández-Barajas Oscar Vidal-Gutiérrez Lauro Gómez-Guerra Omar A. Zayas-Villanueva Access to treatment among patients with advanced kidney cancer in Mexico Medicina Universitaria Kidney cancer. Advanced. Access to treatment. Mexico. Latin America. |
| title | Access to treatment among patients with advanced kidney cancer in Mexico |
| title_full | Access to treatment among patients with advanced kidney cancer in Mexico |
| title_fullStr | Access to treatment among patients with advanced kidney cancer in Mexico |
| title_full_unstemmed | Access to treatment among patients with advanced kidney cancer in Mexico |
| title_short | Access to treatment among patients with advanced kidney cancer in Mexico |
| title_sort | access to treatment among patients with advanced kidney cancer in mexico |
| topic | Kidney cancer. Advanced. Access to treatment. Mexico. Latin America. |
| url | https://www.medicinauniversitaria.org/frame_esp.php?id=178 |
| work_keys_str_mv | AT carlosesalazarmejia accesstotreatmentamongpatientswithadvancedkidneycancerinmexico AT antoniopineiromartinez accesstotreatmentamongpatientswithadvancedkidneycancerinmexico AT angelaljuarezvillarreal accesstotreatmentamongpatientswithadvancedkidneycancerinmexico AT ariannaejararios accesstotreatmentamongpatientswithadvancedkidneycancerinmexico AT anapibarraalaniz accesstotreatmentamongpatientswithadvancedkidneycancerinmexico AT blancaowimercastillo accesstotreatmentamongpatientswithadvancedkidneycancerinmexico AT davidhernandezbarajas accesstotreatmentamongpatientswithadvancedkidneycancerinmexico AT oscarvidalgutierrez accesstotreatmentamongpatientswithadvancedkidneycancerinmexico AT laurogomezguerra accesstotreatmentamongpatientswithadvancedkidneycancerinmexico AT omarazayasvillanueva accesstotreatmentamongpatientswithadvancedkidneycancerinmexico |